For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.